

SUPPLEMENTARY MATERIALS

Patient-reported outcome instruments in non-muscle-invasive bladder cancer (NMIBC): A systematic review

Authors

Ingolf Griebsch¹, Sunil Shrestha^{2,3}, Carolyn C Gotay⁴, John L. Gore⁵, Fran Curtis⁶, Andrew Bottomley⁷

¹Global Health Economics & Outcome Research, Ferring Pharmaceuticals A/S, Ferring International Pharma Science Center, 2770 Copenhagen, Denmark

²Person-Centred Research Directorate, Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia

³Nepal Health Research and Innovation Foundation, Nepal

⁴School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3 Canada

⁵Department of Urology, University of Washington, 1959 NE Pacific St, Seattle, WA 98195, USA

⁶Bladder Cancer Advisory Network, 4520 East West Highway, Suite 610, Bethesda, MD 20814, USA

⁷Bottomley Consulting Group, Brussels, Belgium

Corresponding Author

Sunil Shrestha, PhD.

Email ID: sunilcresta@gmail.com

Co-author details

Ingolf Griebsch: ingolf.Griebsch@ferring.com

Sunil Shrestha: sunilcresta@gmail.com

Carolyn C Gotay: carolyn.gotay@ubc.ca

John Gore: jlgore@uw.edu

Fran Curtis: franrtr@gmail.com

Search Strategy

Embase Classic+Embase <1947 to 2025 June 20>

- 1 "Urinary Bladder Neoplasms".mp. or exp bladder tumor/ 128904
- 2 "non-muscle invasive bladder cancer".mp. or exp non muscle invasive bladder cancer/
10010
- 3 NMIBC.mp. 6258
- 4 exp bladder cancer/ or "superficial bladder cancer".mp. 103196
- 5 1 or 2 or 3 or 4 129265
- 6 "Patient Reported Outcome Measures".mp. or exp patient-reported outcome/ 84586
- 7 "Quality of Life".mp. or exp "quality of life"/ 990088
- 8 "patient-reported outcome*".mp. 104453
- 9 PRO.mp. 493904
- 10 PROM.mp. 10798
- 11 6 or 7 or 8 or 9 or 10 1526465
- 12 "Questionnaires".mp. or exp questionnaire/ 1212467
- 13 instrument*.mp. 611195
- 14 tool*.mp. 1601599
- 15 scale*.mp. 2082823
- 16 measure*.mp. 6118920

17 12 or 13 or 14 or 15 or 16 9646318

18 validat*.mp. 1403318

19 psychometric*.mp. 89306

20 exp reliability/ or reliability.mp. 434728

21 "content validity".mp. or content validity/ 22932

22 "construct validity".mp. or exp construct validity/ 39651

23 interpretability.mp. 13353

24 exp minimal clinically important difference/ or MCID.mp. 10320

25 FDA.mp. or exp "Food and Drug Administration"/ 209835

26 EMA.mp. or exp European Medicines Agency/ 28877

27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 2014083

28 5 and 11 and 17 and 27 442

29 limit 28 to yr="2000 -Current" 439

APA PsycInfo <1806 to June 2025 Week 3>

1 "Urinary Bladder Neoplasms".mp. or exp bladder tumor/ 109

2 "non-muscle invasive bladder cancer".mp. or exp non muscle invasive bladder cancer/
11

3 NMIBC.mp. 8

4	exp bladder cancer/ or "superficial bladder cancer".mp.	3
5	1 or 2 or 3 or 4115	
6	"Patient Reported Outcome Measures".mp. or exp patient-reported outcome/	2207
7	"Quality of Life".mp. or exp "quality of life"/	120551
8	"patient-reported outcome*".mp.	6711
9	PRO.mp.	25164
10	PROM.mp.	622
11	6 or 7 or 8 or 9 or 10	148763
12	"Questionnaires".mp. or exp questionnaire/	243640
13	instrument*.mp.	185185
14	tool*.mp.	225173
15	scale*.mp.	925538
16	measure*.mp.	1097902
17	12 or 13 or 14 or 15 or 16	1937449
18	validat*.mp.	144950
19	psychometric*.mp.	147921
20	exp reliability/ or reliability.mp.	134464
21	"content validity".mp. or content validity/	7104

22 "construct validity".mp. or exp construct validity/ 29763

23 interpretability.mp. 1981

24 exp minimal clinically important difference/ or MCID.mp. 272

25 FDA.mp. or exp "Food and Drug Administration"/ 4728

26 EMA.mp. or exp European Medicines Agency/ 2359

27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 337866

28 5 and 11 and 17 and 27 5

29 limit 28 to yr="2000 -Current" 5

Ovid MEDLINE(R) ALL <1946 to June 20, 2025>

1 "Urinary Bladder Neoplasms".mp. or exp bladder tumor/ 67596

2 "non-muscle invasive bladder cancer".mp. or exp non muscle invasive bladder cancer/
4019

3 NMIBC.mp. 3096

4 exp bladder cancer/ or "superficial bladder cancer".mp. 67400

5 1 or 2 or 3 or 468938

6 "Patient Reported Outcome Measures".mp. or exp patient-reported outcome/ 28292

7 "Quality of Life".mp. or exp "quality of life"/ 532574

8 "patient-reported outcome*".mp. 54406

9 PRO.mp. 304395

10 PROM.mp. 6483

11 6 or 7 or 8 or 9 or 10 864536

12 "Questionnaires".mp. or exp questionnaire/ 1435952

13 instrument*.mp. 1070978

14 tool*.mp. 1176391

15 scale*.mp. 1367517

16 measure*.mp. 4520025

17 12 or 13 or 14 or 15 or 16 7876683

18 validat*.mp. 972434

19 psychometric*.mp. 128319

20 exp reliability/ or reliability.mp. 252853

21 "content validity".mp. or content validity/ 15098

22 "construct validity".mp. or exp construct validity/ 28950

23 interpretability.mp. 11732

24 exp minimal clinically important difference/ or MCID.mp. 4270

25 FDA.mp. or exp "Food and Drug Administration"/ 92338

26 EMA.mp. or exp European Medicines Agency/ 14454

27 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 1339455

28 5 and 11 and 17 and 27 143

29 limit 28 to yr="2000 -Current" 140

EBM Reviews - Cochrane Central Register of Controlled Trials <May 2025>

1 "Urinary Bladder Neoplasms".mp. or exp bladder tumor/ 2404

2 "non-muscle invasive bladder cancer".mp. or exp non muscle invasive bladder cancer/
928

3 NMIBC.mp. 670

4 exp bladder cancer/ or "superficial bladder cancer".mp. 2540

5 1 or 2 or 3 or 43158

6 "Patient Reported Outcome Measures".mp. or exp patient-reported outcome/ 3827

7 "Quality of Life".mp. or exp "quality of life"/ 174873

8 "patient-reported outcome*".mp. 17405

9 PRO.mp. 19026

10 PROM.mp. 1132

11 6 or 7 or 8 or 9 or 10 199751

12 "Questionnaires".mp. or exp questionnaire/ 126855

13 instrument*.mp. 60804

14	tool*.mp.	57006	
15	scale*.mp.	310237	
16	measure*.mp.	602292	
17	12 or 13 or 14 or 15 or 16	868784	
18	validat*.mp.	57395	
19	psychometric*.mp.	7672	
20	exp reliability/ or reliability.mp.	14876	
21	"content validity".mp. or content validity/	778	
22	"construct validity".mp. or exp construct validity/	1421	
23	interpretability.mp.	301	
24	exp minimal clinically important difference/ or MCID.mp.	1454	
25	FDA.mp. or exp "Food and Drug Administration"/	11573	
26	EMA.mp. or exp European Medicines Agency/	1545	
27	18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26	88458	
28	5 and 11 and 17 and 27	21	
29	limit 28 to yr="2000 -Current"	21	

Scopus

(TITLE-ABS-KEY (validat* OR psychometric* OR reliability OR "content validity" OR "construct validity" OR interpretability OR "minimal clinically important difference" OR mcid OR fda OR ema OR "regulatory use")) AND (TITLE-ABS-KEY (questionnaire* OR instrument* OR scale* OR tool* OR measure*)) AND (TITLE-ABS-KEY ("patient-reported outcome*" OR pro OR prom OR "quality of life")) AND (TITLE-ABS-KEY ("non-muscle invasive bladder cancer" OR nmibc OR "superficial bladder cancer"))) 33

Web of Science

("Urinary Bladder Neoplasms+") OR "non-muscle invasive bladder cancer" OR NMIBC OR "superficial bladder cancer") AND ("Patient Reported Outcome Measures") OR "patient-reported outcome*" OR PRO OR PROM OR "quality of life" OR "Quality of Life+") AND ("Surveys and Questionnaires+") OR questionnaire* OR instrument* OR tool* OR scale* OR measure*) AND (validat* OR psychometric* OR reliability OR "content validity" OR "construct validity" OR interpretability OR "minimal clinically important difference" OR MCID OR FDA OR EMA OR "regulatory use") 9